Resolution Therapeutics Announces Regenerative Macrophage Therapy (RMT) Manufacturing Process & Candidate Testing Suite at ASGCT 2025
– Proprietary manufacturing process enables robust and scalable GMP-compliant manufacture of autologous engineered RMT products, including lead asset RTX001 in end-stage liver disease (ESLD).
– Novel mode of action-based candidate testing suite enabled the discovery of RTX001, which shows enhanced anti-inflammatory and anti-fibrotic effects in vitro and in vivo.
– The EMERALD Phase1/2 interventional study for RTX001 (NCT06823713) is now actively recruiting and will investigate the safety and efficacy of RTX001 in patients with ESLD who have recovered from a recent hepatic decompensation.
Edinburgh and London, UK, 14 May 2025 – Resolution Therapeutics (“Resolution” or “Company”), a clinical-stage biopharmaceutical company pioneering regenerative macrophage therapy to treat inflammatory and fibrotic diseases, shares key data from two presentations at the American Society of Gene & Cell Therapy (ASGCT) 28th Annual Meeting in New Orleans, US, May 13-17, 2025.
